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Kornelis S. M. van der Geest, Annemieke M. H. Boots, Maria Sandovici and
Elisabeth Brouwer
Vasculitis Expertise Centre Groningen, Department of Rheumatology and Clinical Immunology, University of Groningen,
University Medical Centre Groningen, Groningen, Netherlands
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are inflammatory diseases
requiring long-term glucocorticoid treatment. Limited data on dynamics in leukocyte
counts before, during and after treatment are available. Leukocyte counts were
measured, as cellular markers of inflammation, at fixed time points in our prospectively
studied cohort of pre-treatment glucocorticoid-naive GCA (N = 42) and PMR (N = 31)
patients. Values were compared with age-matched healthy controls (HCs; N = 51)
and infection controls (N = 16). We report that before start of treatment monocyte
and neutrophil counts were higher in GCA and PMR patients than in HCs, while
NK- and B-cell counts were lower. C-reactive protein (CRP) levels correlated positively
with monocyte counts in GCA, and negatively with B-cell and NK-cell counts in
PMR. During glucocorticoid treatment, myeloid subsets remained elevated whereas
lymphoid subsets tended to fluctuate. Interestingly, erythrocyte sedimentation rate (ESR)
outperformed CRP as marker for relapses in GCA. We defined stable treatment-free
remission groups in both GCA and PMR. GCA patients in treatment-free remission still
demonstrated elevated monocytes, neutrophils, ESR, and platelets. PMR patients in
treatment-free remission had normalized levels of inflammation markers, but did have
elevated monocytes, lowered CD8+ T-cell counts and lowered NK-cell counts. Finally,
we showed that low hemoglobin level was predictive for long-term GC treatment in
PMR. Overall, leukocyte composition shifts toward the myeloid lineage in GCA and
PMR. This myeloid profile, likely induced by effects of inflammation on hematopoietic
stem cell differentiation, persisted during glucocorticoid treatment. Surprisingly, the
myeloid profile was retained in treatment-free remission, which may reflect ongoing
subclinical inflammation.
Keywords: giant cell arteritis, polymyalgia rheumatica, vasculitis, glucocorticoids, longitudinal cohort study,
relapses, treatment-free remission
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INTRODUCTION
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR)
are aging-related inflammatory diseases that frequently overlap
(1). GCA and Takayasu arteritis both belong to the large vessel
vasculitis, but GCA only occurs in the elderly and can also
affect cranial arteries. Involvement of cranial arteries (C-GCA)
is associated with cranial symptoms including headache, jaw
claudication, and vision loss. Large vessel GCA (LV-GCA) is
more difficult to diagnose due to non-specific symptoms such
as weight loss and low-grade fever. PMR is characterized by
bursitis and synovitis leading to pain and stiffness mainly in the
shoulder and hip girdle (2). PMR is diagnosed in up to 60% of
GCA patients (3), implying overlapping pathogenic pathways.
The pathogenesis of GCA, and especially PMR, are incompletely
understood (4). In GCA, temporal artery biopsies (TABs) reveal
a granulomatous infiltrate of macrophages and CD4+ T-cells
in the vessel wall (5, 6). Infiltrating B-cells and neutrophils
have been found in lower numbers (7–10). The vast majority
of newly diagnosed GCA and PMR patients display elevated
interleukin (IL)-6-dependent acute-phase markers such as ESR
and CRP (11, 12). From the 1950s until now, glucocorticoids
(GCs) have remained the cornerstone of treatment in GCA
and PMR (13). GC treatment, however, is accompanied by
side-effects, and relapses during GC treatment are common
(14, 15). More recently, progress has been made regarding GC-
sparing therapies in GCA and PMR (16–18). The effects of
GC-mediated immunosuppression are pleiotropic and not yet
completely understood (19). GCs strongly repress the acute-
phase response (17), and therewith repress the utility of CRP,
ESR, and other inflammatory markers in monitoring patients
during treatment. Furthermore, recent evidence suggests that
GCA patients on GC treatment with a normal CRP/ESR
and absence of symptoms can still have persistent vessel wall
inflammation (20–22). Consequently, it is unknown whether
patients who reached treatment-free remission are truly in
remission or are suffering from ongoing subclinical disease. This
is important, as GCA patients with subclinical vasculitis are
at risk of aneurysm development and aortic dissection (1, 23).
In search for cellular markers of inflammation in GCA and
PMR, we documented leukocyte dynamics during the entire
disease course. Previously, altered monocyte, neutrophil, and B-
cell blood counts have been reported at diagnosis (9, 24, 25).
In addition, small and mostly short-term studies have addressed
the effect of GCs on blood leukocyte subset counts in GCA and
PMR patients. Both myeloid [monocytes (25, 26), neutrophils
(10, 24)] and lymphoid [CD4+/CD8+ T-cells (26–28), B-cells
(9), NK-cells (26, 29)] cell counts appear to be affected by GCs.
However, to the best of our knowledge, a comprehensive long-
term study comparing leukocyte subset counts before, during
and after GC treatment in GCA and PMR patients has not been
performed. The current study was conducted in our prospective
cohort in which glucocorticoid-naive GCA and PMR patients
were requested to participate at diagnosis and were followed
for up to 7 years. At fixed time points, leukocyte counts and
other inflammatory markers were determined. We investigated
the effects of disease on leukocyte subsets by comparison to
healthy and infection controls. Next, we analyzed the effects of
short- and long-term treatment on leukocyte subsets in GCA
and PMR patients and extended our investigation to patients
who had reached stable treatment-free remission. In addition, we
evaluated the usefulness of leukocyte subsets and inflammatory
markers in identifying relapses and assessed their prognostic
value before start of treatment.
MATERIALS AND METHODS
Patient Population
Characteristics of newly-diagnosed patients before start of
treatment and characteristics of controls are displayed in
Table 1. Forty-two GCA and 31 PMR patients participated
in our cohort study and were seen at the Rheumatology
and Clinical Immunology outpatient clinic of the University
Medical Center Groningen between 2010 and 2018. These
patients did not use GCs or other disease modifying anti-
rheumatic drugs (DMARDs) at pre-treatment assessment. GCA
patients were diagnosed based on a positive temporal artery
biopsy (TAB) and/or a positive 18F-fluorodeoxyglucose-positron
emission tomography-computed tomography (FDG-PET-CT)
for LV-GCA. In GCA 29 of the 42 patients fulfilled the 1990
ACR criteria, as these criteria are mainly useful in diagnosis of C-
GCA rather than LV-GCA. Diagnosis of PMR patients was based
on a positive FDG-PET-CT scan, or based on clinical signs and
symptoms if no FDG-PET-CT could be performed. Twenty-five
out of 31 PMR patients fulfilled the Chuang criteria. Three PMR
patients without a FDG-PET-CT scan, did not fulfill the Chuang
criteria due to ESR levels below 40mm/h, but did have elevated
CRP levels (>10mg/L). All but one PMR patient fulfilled the
preliminary ACR/EULAR 2012 classification criteria (30). This
patient did fulfill the Chuang criteria and had a positive FDG-
PET-CT for PMR. This study included cross-sectional data of
51 age- and sex-matched HCs and also 16 age-matched INFs.
HCs were screened for past and present morbidities. Hospitalized
INFs who suffered from urinary tract infection (n = 10) or
pneumonia (n = 6) were requested to participate. All INFs were
recruited during active infection, up to 7 days after admission to
the hospital. Volunteers in both control groups did not take any
immunosuppressive drugs nor had comorbid diseases. Written
informed consent was obtained from all study participants. All
procedures were in compliance with the declaration of Helsinki.
The study was approved by the institutional review board of the
University Medical Center Groningen (METc2012/375 for HC
and METc2010/222 for GCA, PMR, and INF).
Follow-Up and Treatment
GCA and PMR patients were prospectively followed for a
median period of 30 (range 0–71) and 46 months (range 0–
75), respectively. For nine patients, only a pre-treatment visit
could be included. We did not exclude these patients to make
the pre-treatment data stronger. The number of GCA patients
followed for 1 year was 31 (72%) and the number of GCA
patients followed for 2 years was 23 (54%). For PMR the number
of patients followed for 1 year was 24 (83%) and the number
of patients followed for 2 years was 20 (69%). Patient visits
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TABLE 1 | Pre-treatment characteristics of newly diagnosed, treatment-naive giant cell arteritis and polymyalgia rheumatica patients, aged healthy controls, and aged
infection controls.





















Females (%) 32 (63) 28 (67) 20 (65) 5 (31) NS NS 0.043
Smoking status;
smoking/non-smoking
9/42 13/29 3/28 4/10 NS NS NS
TAB
positive/performed
NA 23/29 0/6 NA – – –
FDG-PET-CT positive for
GCA/PMR/GCA+PMR
























































*n for Interleukin-6 is as follows HC= 17, GCA= 40, PMR= 29, INF= 13. HC, healthy control; INF, infection control; TAB, temporal artery biopsy; FDG-PET-CT, 18F-fluorodeoxyglucose-
positron emission tomography-computed tomography; IL-6, interleukin-6; Hb, hemoglobin; NS, not significant.
were planned according to a fixed protocol. For analysis, follow-
up visits were stratified into three groups: treatment phase
I (2, 6 weeks, and 3 months), treatment phase II (6 and 9
months) and treatment phase III (12 months and thereafter
every 6 months). All patients in treatment phase I, II and III
still receive treatment. GCA patients started with a higher daily
GC dose than PMR patients (median 60mg in GCA, 15mg
in PMR). GCs were tapered upon remission according to BSR
guidelines for GCA (31) and for PMR (32). In this study, a
relapse is defined by GCA- or PMR-specific signs and symptoms.
In case of a relapse, an extra visit to the outpatient clinic was
scheduled; daily GC dose was increased and/or a conventional
synthetic DMARD (methotrexate or leflunomide) was added to
the treatment regimen. None of the patients in this study used IL-
6 receptor blockade (e.g., tocilizumab). In patients that remained
in remission, GC and/or DMARD treatment was tapered until
treatment-free remission was achieved. In order to analyse stable
treatment-free remission, we excluded samples from the first 3
months of treatment-free remission and hereafter only included
samples of patients who did not show return of signs and
symptoms for at least 6 months.
Laboratory Measurements
Basic laboratory measurements of CRP, ESR, Hb, and platelets
as well as blood leukocyte counts were collected at all available
time points. CRP levels were determined using the Cobas 8000
modular analyser (Roche, Basel, Switzerland). ESR (Westergren
method) and Hb were determined by the XN-9000 (Sysmex,
Kobe, Japan). Platelets, monocytes and neutrophil counts were
also determined by the XN-9000, based on size and granularity
(diff). Levels of serum IL-6 (standard curve range 4.8–1,154;
sensitivity 1.7 pg/ml) were measured with Human premix
Magnetic Luminex screening assay kits (R&DSystems, Abingdon,
UK) only pre-treatment [see previous study (12)]. Absolute
counts of lymphocyte subsets were measured in EDTA blood
by the BD (San Jose, CA, USA) MultiTest TruCount method,
as described by the manufacturer. Lymphocytes were gated
by size and positivity for CD45, after which the subsets
were defined: CD4+ T-cells (CD3+CD4+), CD8+ T-cells
(CD3+CD8+), B-cells (CD19+), and NK-cells (CD56+ and/or
CD16+). TruCount measurements were performed on a FACS
Canto-II (BD) and subsequently analyzed with FACSCanto
Clinical Software. Monocyte counts were also determined by
the TruCount method, which is based on size, granularity, and
CD45 expression. We determined that counts of monocytes
were 22% higher when measured by the XN-9000 method
compared with the TruCount method. This factor was stable
throughout all samples. Comparison of 20 samples measured by
both methods and corrected (x 1.22), showed a strong correlation
(r = 0.87, p= <0.0001) and good agreement on a Bland-Altman
plot (Supplementary Figure 1). For this reason we applied this
correction to all monocyte count measurements assessed by the
TruCount method.
Statistical Analysis
To analyse differences between groups and over time, 2-tailed
non-parametric tests were performed. Fisher’s exact test, Kruskal
Wallis, and Mann Whitney U-tests were used when comparing
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patients with controls. Strength and statistical significance of
correlations between measurements was tested using Spearman’s
rank correlation. The log rank test was used to compare the
time to GC-free remission between patients with low or high
inflammatory markers or cell counts pre-treatment. Analyses
were performed with IBM SPSS 23 and GraphPad Prism
7.02 software.
RESULTS
Pre-treatment: Altered Levels of IL-6, CRP,
ESR, Hb, and Platelets in GCA and PMR
Patients
IL-6, CRP, ESR, and platelet counts were significantly higher
whereas Hb levels were significantly lower for pre-treatment
FIGURE 1 | Pre-treatment measurements in newly-diagnosed, treatment naive GCA and PMR patients. (A), Leukocyte counts in the blood for GCA and PMR as well
as two control groups: HC and INF. The n is depicted in the figure and indicates the number of samples measured in the different groups. Data is expressed as
median and interquartile range. Statistical differences by Mann Whitney U between groups are displayed if Kruskal Wallis testing indicated significant differences:
*p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001. (B), Stacked leukocyte subset counts show a clear shift to the myeloid lineage in GCA and PMR pre-treatment.
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GCA and PMR patients compared to HCs (Table 1). IL-6, CRP,
ESR, and Hb did not differ between GCA or PMR patients and
infection controls (INFs), but platelet counts were significantly
higher in GCA (p = 0.008) and PMR (p = 0.033) than in
INFs. Smoking status did not differ between patients groups.
In GCA, CRP, and ESR correlated positively (Rho = 0.80),
whereas no correlation was observed in PMR (Rho = 0.36,
NS; Supplementary Figure 2). In addition, hemoglobin (Hb)
correlated negatively with ESR in both patient populations
(GCA Rho = −0.51, PMR Rho = −0.65). In GCA patients,
platelet counts correlated positively with CRP and ESR (Rho
= 0.49 and Rho = 0.54, respectively), and negatively with
Hb (Rho=−0.39).
Leukocyte Subsets in Pre-treatment GCA
and PMR Patients: Shift to the Myeloid
Lineage
Absolute counts of leukocyte subsets measured in GCA and
PMR patients before start of treatment were compared with
counts in HCs and INFs (Figure 1A). Counts of neutrophils
and monocytes were significantly higher, while NK-cells were
significantly lower in GCA and PMR patients compared to
HCs. Counts of these subsets in patients were similar to those
in INF. B-cell counts were also significantly lower in PMR
while for GCA patients a trend toward reduction of B-cells
was observed (p = 0.06). In contrast, T-cells (both CD4+
and CD8+) in GCA and PMR patients were not significantly
different from HC, even though T-cell counts were lower
in INFs. Overall, we observed a shift in leukocyte counts
toward the myeloid lineage in both GCA and PMR patients
as myeloid cell counts were elevated, while lymphoid cell
counts were reduced or unchanged (Figure 1B). To determine
a possible involvement of leukocyte subsets in disease activity,
we correlated numbers of circulating leukocyte subsets with CRP
levels determined at the same visit (Figure 2). A significant
positive correlation was observed between monocyte counts
and CRP in GCA-patients only (Rho = 0.58), whereas CRP
from PMR patients correlated negatively with numbers of
circulating B-cells (Rho = −0.55) and NK-cells (Rho = −0.52).
In addition, CRP from INFs showed a strong correlation
with neutrophil counts (Rho = 0.70). For all correlations,
see Supplementary Figure 2.
During Treatment: Myeloid Subsets
Remain Elevated Whereas Lymphoid
Subsets Fluctuate
After diagnosis and pre-treatment sampling, all patients started
with GC treatment. To visualize fluctuations in absolute
leukocyte counts during follow-up in both GCA and PMR, a
(smoothed) median of 20 consecutive measurements over time
was calculated and depicted in Figure 3. To apply an appropriate
statistical analysis of treatment effects over time and to compare
it with the HC group, the follow-up time was split into three
treatment phases as depicted in Figures 3, 4. Median daily GC
dose successively decreased for GCA patients in treatment phase
I, II, and III: 40, 10, and 5mg, respectively. In PMR patients
this was 15, 7.5, and 5mg. In both GCA and PMR patients
on treatment, myeloid cell counts (monocytes and neutrophils)
remained higher over time compared to HCs (Figures 3, 4).
Neutrophils increased further during treatment phase I and II
when compared to pre-treatment. Lymphoid cells (NK-, T-, and
B-cells) were also affected by treatment. B-cells showed most
fluctuations over time: during treatment phase I, we observed
an increase compared to pre-treatment which was followed by a
progressive decrease in treatment phase II and III. T-cell (CD4+
and CD8+) counts were low during treatment compared to pre-
treatment and to HC counts. Interestingly, T-cell counts dropped
significantly during treatment phase I in GCA patients, while
this was not observed in PMR patients where T-cells were only
lowered in phase II and III. NK-cells remained significantly
lower throughout all phases compared to HCs. Platelets, CRP,
and ESR all decreased from pre-treatment levels during the
entire treatment but mostly remained elevated when compared
to HCs (Supplementary Figure 3). In GCA patients platelets
were elevated in all phases, but CRP and ESR were elevated
only in phase II and III. In PMR patients platelets were elevated
in phase I, CRP in phase I and II and ESR in phase II and
III. Hb increased from pre-treatment levels in both GCA and
PMR but remained decreased compared to HC levels during
all phases.
FIGURE 2 | Correlations between three leukocyte subsets and the inflammatory marker CRP. Correlations between CRP and the leukocyte subset in pre-treatment
GCA (closed circles) and PMR (open circles) patients. Spearman’s R, the p-value of the correlation and the N are indicated in each graph for GCA and PMR.
Regression line for GCA is shown as an uninterrupted line, for PMR as a dotted line. Correlations for neutrophils, CD4+ T-cells, and CD8+ T-cells are displayed in
Supplementary Figure 2.
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FIGURE 3 | Smoothed median of leukocyte counts for GCA and PMR patients over time while on GC treatment. The smoothed median is calculated by taking the
median of each new measurement and that of the 19 measurements before that point. This method enables to distinguish patterns over time that would be
unnoticeable if each point is plotted separately. For interpretation the interquartile range of HC (green box, cross-sectional measurement) and the median of the INF
(dotted line, cross-sectional) were added to the figures. Time point 0 indicates the pre-treatment sample. Also, the three different treatment phases are indicated.
ESR Outperforms CRP, Hb, and Platelets
as Marker for Relapses in GCA During
Treatment
In order to determine the GC dose at which patients experienced
a relapse, the daily GC dose of patients who were followed
for at least 2 years was recorded (Table 2). Of the 24 GCA
patients fulfilling this criterion, 79% experienced at least one
relapse during these 2 years. In addition, 57% of the 21 PMR
patients developed at least one relapse during this period. The
median daily dose at relapse was 5mg for GCA and 7.5mg
for PMR. Six GCA relapses and five PMR relapses occurred in
patients who were not taking GCs anymore. Next, we determined
whether levels of inflammatory markers and leukocyte counts
were different in relapsing patients compared to patients in
treatment-induced remission (Figure 5). CRP levels did not
reflect relapses in treatment phase I for both GCA and PMR
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FIGURE 4 | Dynamics in cell population counts during follow-up in GCA (A) and PMR (B) patients. Counts are expressed in radar plots as median fold-change
compared to healthy controls (n = 51) for the following groups: pre-treatment (GCA n = 42, PMR n = 31), treatment phase I (GCA n = 38, 69 measurements; PMR n
= 25, 54 measurements), phase II (GCA n = 32, 43 measurements; PMR n = 23, 33 measurements), and phase III (GCA n = 29, 65 measurements; PMR n = 19, 56
measurements). Pre-treatment only includes the visit before start of treatment; treatment phase I includes follow-up visits at 2, 6 weeks, and 3 months; treatment
phase II includes 6 and 9 months; treatment phase III includes 12 months and beyond.
†
: sign difference between HC and baseline, ×: sign difference between HC
and treatment phase I, #: significant differences between HC and phase II, and ¤: significant differences between HC and phase III (Mann-Whitney U-test, P < 0.05).
TABLE 2 | Daily glucocorticoid dose use at the time of relapse for GCA (N = 24)







0 6 (21) 5 (25)
1–5 10 (35) 3 (15)
6–10 7 (24) 6 (30)
11–20 6 (21) 5 (25)
>20 0 1 (5)
Total 29 20
In patients that were followed for 2 years, we registered the daily GC dose at which they
relapsed. Relapses were defined by clinical signs and symptoms only. GC, glucocorticoid;
GCA, giant cell arteritis; PMR, polymyalgia rheumatica.
patients when compared to remission patients. In PMR this was
also true for treatment phase II. ESR, however, did discriminate
GCA patients experiencing a relapse from remission patients in
all treatment phases. In PMR patients this was only the case for
treatment phase III. Lower Hb and higher platelets were observed
in relapsing GCA patients during phase II and in relapsing PMR
patients during phase III. There were also differences in leukocyte
counts between relapsing and remission patients in PMR. During
relapses, patients displayed higher CD4+ T-cells in treatment
phase I, lower NK-cells in phase II, and higher neutrophils in
phase II and III (data not shown).
The Myeloid and Inflammatory Profiles
Persist in Treatment-Free Remission
Patients
To determine whether leukocyte counts and inflammatory
markers of GCA and PMR patients are truly normalized after
treatment cessation, we investigated patients in treatment-
free remission (defined as 3 months treatment-free and in
stable remission for the next 6 months). So far, 13 GCA and
15 PMR patients have reached treatment-free remission and
were included in the analysis. GCA patients in treatment-
free remission showed persistently elevated myeloid cell counts
compared to HCs. Note that, compared to pre-treatment
levels, neutrophil counts were found reduced (Figure 6A). PMR
patients in treatment-free remission also still demonstrated
significantly elevated myeloid cell counts although monocyte
counts had decreased since pre-treatment levels (Figure 6B).
Furthermore, NK-cell and CD8+ T-cell counts were lower in
PMR treatment-free remission patients than in HCs. In GCA,
there was a strong trend toward lower NK-cells in treatment-free
remission compared to HCs (p = 0.05). Inflammatory markers
normalized to HC levels in PMR patients in treatment-free
remission (Figure 6C). In contrast, in treatment-free remission
GCA elevated ESR and platelet counts and lowered Hb remained,
whereas CRP was normal. We further investigated whether
the elevated ESR in GCA patients was linked to changes
in leukocyte subsets. We found a strong negative correlation
between B-cell counts and ESR in treatment-free remission GCA
patients (Figure 6D).
Pre-treatment Low Hb Predicts Longer GC
Requirement in PMR
Finally, we assessed whether leukocyte subset counts and
inflammatory markers, assessed before start of treatment, could
predict time to GC-free remission. A predictive factor was found
in PMR patients, only. Pre-treatment Hb level higher than the
median, predicted a short time to GC-free remission (i.e., a
favorable disease course) compared to patients with a low Hb
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FIGURE 5 | Levels of inflammatory markers during treatment phase I, II, and III for GCA and PMR patients in remission and during relapse. The definition of remission
and relapse was based solely on clinical signs and symptoms. Data is expressed as median plus interquartile range. The number of measurements is indicated by n.
Statistical significance is expressed as follows: *p < 0.05, **p < 0.01, ****p < 0.0001 (Mann Whitney U-test).
before start of treatment (Figure 7, p = 0.025). As the Hb is
typically higher inmales, we checked the sex distribution between
PMR patients with low and high Hb and found an exact equal
distribution. The other inflammatory markers, CRP, and ESR,
were not prognostic for GC requirement, nor were any of the
leukocyte subset counts.
DISCUSSION
This prospective study provides a comprehensive overview of
peripheral blood leukocyte dynamics and inflammatory markers
in GCA and PMR during the entire disease course: before
and after start of glucocorticoid treatment as well as in stable
treatment-free remission. Our main finding is that leukocyte
counts shift to the myeloid lineage in both GCA and PMR and
that this myeloid bias persists in spite of GC treatment and
extends well into treatment-free remission.
Counts of myeloid leukocyte subsets were elevated in pre-
treatment GCA and PMR patients. This may be explained by
the actions of IL-6, a key pro-inflammatory cytokine in GCA
and PMR, promoting monocyte and neutrophil production in
the bone marrow (33). In contrast to myeloid subset counts,
pre-treatment lymphoid subset counts were either lowered
(NK- and B-cells) or unchanged (CD4 and CD8 T-cells). In
INF all lymphoid cell counts were lowered. These findings are
in accordance with the notion that inflammation shifts the
development of hematopoietic stem cells toward the myeloid
lineage (34). Previous studies have mostly documented similar
findings (10, 24–29, 35), albeit that some reported on lowered
monocyte counts (26) and lowered CD8+ T-cells (26, 27).
Typical acute phase markers are elevated in both GCA and
PMR patients, at pre-treatment analysis, even though the ESR
is significantly lower in PMR than in GCA patients. In contrast
to GCA, CRP, and ESR are not correlated with each other
in PMR patients. CRP is considered a more acute marker
of inflammation, while ESR is more associated with longer-
term chronic inflammation (36). The ESR is a composition of
several proteins, including fibrinogen, Hb, and immunoglobulin
levels (37). Whether there is a discrepancy in the ESR of
GCA patients compared to PMR patients, remains to be
investigated. Remarkably, platelet counts were found even higher
than INF. Whether platelet counts are useful as disease-specific
biomarker, needs to be evaluated in a larger cohort. In GCA,
systemic symptoms (e.g., fever, weight loss) are linked to
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FIGURE 6 | Different leukocyte subset counts and inflammatory markers in treatment- free remission. Leukocyte subset counts pre-treatment and in treatment-free
remission (A: GCA n = 13 patients, 17 samples and B: PMR n = 15 patients, 25 samples) were expressed as median fold-change compared to healthy controls.
†
:
sign difference between HC and treatment-free remission. ×: sign difference between pre-treatment and treatment-free remission (Mann-Whitney U-test p < 0.05).
(C) Inflammatory markers in HC, GCA treatment-free remission, and PMR treatment-free remission (Mann-Whitney U-test: ***p < 0.001,****p < 0.0001). Data is
expressed as median and interquartile range. (D) Correlation between B-cell counts and ESR in treatment-free remission patients.
FIGURE 7 | In PMR patients, long-term GC requirement is predicted by pre-treatment Hb levels, but not by CRP and ESR. The CRP, ESR, and Hb of PMR patients
before treatment were split into low or high levels (based on the median) and were plotted in a Kaplan-Meier curve against time to GC-free remission. p-value and
hazard ratio (HR; including 95% confidence interval) of the log rank test are depicted in the graphs.
the IL-6-dependent acute-phase response (38). Previously, we
indeed observed a strong positive correlation between IL-6 and
CRP in our cohort (12). In the current study, we also found
pre-treatment CRP to be positively correlated with monocyte
counts in GCA patients. Monocytes are important in the
immunopathogenesis of GCA and work in tandem with CD4+
T-cells to promote granulomatous inflammation, angiogenesis,
and destruction of the vessel wall (5, 39). Monocytes, as part of
the innate immune system, sense pathogens, and danger signals
by pattern recognition receptors, including toll-like receptors
(TLRs) (40). Previously, TLR7 expression on monocytes of GCA
and PMR patients was found elevated, hinting at a higher
responsiveness to viral antigens (41). The chemokine CCL2 is
important for monocyte migration, and its levels were found
lower in the blood of GCA patients (25). This could be explained
by the usage of CCL2 by monocytes migrating from the bone
marrow to the blood. In pre-treatment PMR, we found a negative
correlation of CRP with B-cells and NK-cells, hinting that
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these cell types are important in the maintenance of immune
homeostasis. This could be through immune regulatory functions
as described before for both subsets (38, 39, 42, 43). Alternatively,
low B-cell and NK-cell counts may reflect tissue migration. It is
currently unknown if B-cells or NK-cells infiltrate PMR synovia
but B-cell counts were found to be decreased in GCA and B-cells
and are present in GCA vessels (8, 9, 44), implying migration.
In GCA, NK-cells are not frequently found in the TABs, arguing
against migration (25).
In this study, we also chartered effects of treatment on
leukocyte subsets and inflammatory markers in GCA and PMR
patients over time. Blood counts of monocytes and neutrophils
remained elevated in patients compared to controls throughout
the entire treatment period. GC-induced leukocytosis is a well-
known phenomenon (45) and is mainly due to the effect
of GCs on neutrophils. GC treatment causes the release of
neutrophils from the marginal pool by decreasing the expression
of adhesion molecules Mac-1 and L-selectin needed to bind
to the endothelium (46, 47). GCs mainly increase counts of
mature neutrophils in the blood, as influx of infection-related,
“non-segmented” neutrophils from the bone marrow is minimal
(45, 47). While monocyte counts remained elevated compared to
HC levels, they were lowered by GC treatment. This is likely due
to a decrease in non-classical monocytes which are sensitive to
GC-induced apoptosis (25, 48). GC-treatment affected lymphoid
leukocyte counts as well. Interestingly, a difference between GCA
and PMR in CD4+ T-cell counts was observed in the first months
of treatment, as these counts were markedly decreased in GCA
patients only. This is likely caused by GCA patients receiving
a higher GC dose. Indeed, high- but not low-dose GCs, have
a strong apoptotic effect on CD4+ T-cells in-vitro and in-vivo
and this decrease is associated with inhibition of IL-2 signaling
(49). Also noticeable is the pattern of B-cells during treatment
in GCA patients; early treatment led to an increase in B-cell
counts. This is likely caused by B-cells returning to the circulation
from peripheral sites (9). In our cohort, patients on long-term
GC treatment became lymphopenic, as especially their CD4+ T-
cell and B-cell counts gradually lowered over time. In addition,
NK-cell counts, that were already lower pre-treatment, were not
found to reduce further on treatment. This is in accordance
with previous reports on NK-cell counts in GCA and PMR and
in line with NK-cells being resistant to GC-induced apoptosis
(26, 29, 49). Overall, long-term GC use significantly changes
the composition of the peripheral leukocyte pool as well as the
function of leukocyte subsets (14, 15), thereby making GCA and
PMR patients susceptible to infections (50).
Our data are in congruence with the notion that GCs
manage to actively suppress symptoms of the disease but have
only a partial effect on tissue inflammation. This is based on
the inflammation-induced myeloid dominance observed before
treatment that persisted during treatment, despite a suppressed
CRP and ESR. Indeed, a too rapid tapering of GCs will in
most cases lead to a return of signs and symptoms (50, 51).
The observed GC dose at which patients experience their
first relapse is in line with previous reports (52). Moreover,
a study investigating sequential TABs revealed that at least
44% of GCA patients have persistent inflammation in spite of
treatment-induced remission (22). Furthermore, recent studies
on tissue inflammation markers during tocilizumab treatment
raise caution for ongoing inflammation despite absence of
symptoms (21, 53).
The strong suppressive effect of GCs on the acute-phase
response makes the classic inflammatory markers, CRP and
ESR, less trustworthy for monitoring disease activity. In the
first months of treatment, solely ESR discriminated between
relapsing and remission GCA patients and the difference in
ESR between these groups were found to become significantly
stronger at later phases and thus at lower GC doses. Overall,
ESR appeared more suited than CRP in identifying relapses in
GCA rendering ESR more useful in monitoring disease activity.
This is in accordance with a previous study on monitoring
biomarkers in GCA (54). However, as described before (55), CRP
and ESR are frequently normal at time of clinical relapse. This
unsatisfactory use of CRP/ESR during GC treatment, and the fact
that tocilizumab treatment suppresses these markers even more
(21), raises the need for new inflammatory markers to aid in
monitoring of GCA and PMR patients. Peripheral blood cells of
GCA and PMR patients in treatment-free remission were found
to retain themyeloid bias. Thismay be explained by a long-lasting
imprint of inflammation on peripheral blood cell composition.
Yet, whereas markers of inflammation normalized in PMR,
these markers (ESR, Hb, and platelet counts, but not CRP)
remained altered in GCA patients that have reached treatment-
free remission. The combined data suggest that subclinical vessel
wall inflammation may still be ongoing in GCA. Alternatively,
this retained myeloid dominance could point toward cellular
senescence of the immune system which had predisposed
the patients to develop these diseases. Indeed, aging of the
immune system has been linked to development of disease
(56). Interestingly, this ongoing response (ESR) is negatively
correlated with B-cell counts. B-cells might be important in
preventing a return of disease and/or B-cells might aggravate
disease by tracking to the site of inflammation. Migration
of B-cells toward the inflamed vessel has been documented
in GCA (7, 8, 44) but their role in the tissue (either anti-
or pro-inflammatory) remains to be established. Thus, the
question remains whether symptom treatment of GCA (and
PMR) is sufficient. Persistence of the myeloid and inflammatory
profile suggests ongoing inflammation eventually leading to
vascular damage and associated morbidity and mortality (57).
Additionally, we discovered a prognostic value of pre-treatment
Hb levels on disease course in PMR patients. Our data show that
patients with a low Hb have a higher risk for an unfavorable
long-term disease course. No such prognostic value was seen
for ESR and CRP. The low pre-treatment level of Hb in PMR
patients is a secondary effect of long-term inflammation (58). We
thus hypothesize that a low Hb better reflects the inflammatory
load over a longer period of time than ESR and especially CRP.
The latter inflammatory markers are indeed more prone to
fluctuate over time (36). The clinical utility of our finding is that
low Hb levels may predict long-term GC requirement in PMR
patients. The major strength of this study is our well-defined,
prospectively followed, long-term cohort of GCA and PMR
patients who joined the study when they were treatment-naive,
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allowing to assess pre-treatment values. Often, GCA and PMR
patients are included in cohorts after start of GCs. The strict
follow-up regimen allowed us to investigate the immune status
of patients during relapses and in treatment-free remission.
Because of the clinical overlap between the two diseases, the
drawn comparisons in this study are useful. The inclusion of
the INF group helped to discriminate between disease specific
and non-specific features. Another strength of the study is that
we documented changes in six major peripheral blood leukocyte
subsets using assays that are readily available in the clinical
setting. Our study is limited by sole analysis of peripheral blood
markers in both these systemic diseases which may only partly
mirror the immunological processes at the sites of inflammation
such as the vessel wall and the synovium in GCA and PMR,
respectively. In conclusion, we observed a clear shift toward
the myeloid lineage in pre-treatment GCA and PMR patients.
This myeloid bias was associated with inflammatory markers
and persisted during glucocorticoid treatment and in treatment-
free remission. Persistence of the myeloid and inflammatory
profile during the entire disease course may reflect ongoing
subclinical vasculitis, implying that current glucocorticoid-
based treatment is unsatisfactory. Future studies using sensitive
imaging techniques should address if these profiles indeed
coincide with tissue inflammation. Also, treatment could aim
at targeting the myeloid shift in GCA and PMR patients.
Blocking the granulocyte macrophage colony stimulating factor
(GM-CSF) receptor could prove to be beneficial in influencing
this shift. Trials with this type of treatment are currently
ongoing (NCT03827018).
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